BioHaven Pharmaceuticals announced the outcome from a focused analysis of the topline co-primary and key secondary data from its Phase 2/3 clinical trial of troriluzole as…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.